GBI Research, the leading business intelligence provider, has released its latest research, “Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications”, which provides insights into the global regenerative medicine therapeutics market. The report provides an in-depth analysis of regenerative medicine and the challenges in translating it into clinical practice, with a focus on stem cell research, gene therapy and tissue engineering. The report also includes insights into the late-stage R&D pipeline for regenerative medicine and the indications of particular interest in terms of development. Some of the countries focusing on regenerative medicine are looked at for their regulatory and research environment. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research has found that the regenerative medicine market has significant potential for growth, despite the low number of currently approved molecules. Regenerative medicine offers a chance to find curative therapies for disease areas with significant unmet need, including orphan diseases and diseases with a high burden globally, such as cancer and diabetes. In addition, the growth of the elderly population offers a large patient base for regenerative therapies. However, translating regenerative medicine from basic research and preclinical work to clinical trials in humans and then into medical practice is a challenging process and many applications are as yet unapproved. Some areas, such as wound healing, have seen some success, but gene therapy and many stem cell applications are as yet in their infancy. The direction of the market and the potential for success are examined in this report, along with an analysis of the currently marketed therapies and promising applications being studied in the pipeline.
Report Highlights More Guidelines Needed to Grow Regenerative Medicine Market, Report Finds
Standardized research guidelines are needed to control and encourage the development of gene therapy and stem cell treatments, according to a new report by healthcare experts GBI Research.
The new report* shows how regenerative medicine is seen as an area with high future potential, as countries need ways to cope with the burden of an aging population.
The stem cell market alone is predicted to grow to around $5.1 billion by 2014, while gene therapy has also shown promise despite poor understanding of some areas of regenerative medicine and a lack of major approvals (the only approvals to date being made in Asia).
Up until now, securing research within clinics has been difficult, with a high number of failures and discontinuations throughout all phases of clinical study. Stem cell therapy uses bone marrow transplants as an established treatment method, but the development of the therapy into further applications and has not yet become common practice.
Similarly, tissue engineering has been successful in the areas of skin and bone grafts, but translation into more complex therapies has been an issue for researchers. Although scientific possibilities are ever-increasing, the true potential of regenerative medicine has yet to be demonstrated fully.
A desire to discover new and innovative technologies has encouraged governments in the UK and Singapore to focus directly on regenerative medicine as a future potential economy booster. They have provided funding and incentives for companies to conduct their research in the country, along with the creation of hubs of knowledge and permissive regulatory environments to encourage research. Funding for industry and research groups is a vital part of furthering regenerative medicine, especially in taking therapies through clinical trials and on to commercialization. As more regions find a desire to attract industry and expertise, more focus is likely to be given to regenerative medicine.
However, uncertainties over legislation and funding from government bodies, especially in regard to ethically controversial therapies such as human embryonic stem cell research, are still deterring investors. President Obama overturned a ruling on a ban on NIH (US National Institutes of Health) funding for human embryonic stem cell research, but a newly elected party may scrap this valuable route of funding.
Regulatory pathways for the new and emerging field of regenerative medicine can create problems. Requirements for clinical trial design, required endpoints and approval legislation are still developing and often differ between countries, creating problems for companies looking to enter markets internationally.
Organizations such as the International Society for Stem Cell Research (ISSCR) publish recommended guidelines on working with stem cells, but these are not binding. Governments must therefore come together to determine a standardized framework for innovative medical research, in order that positive results and long-term follow-up data can be produced to solidify the reputation and investment potential of the regenerative medicine market.
*Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications
This report provides an in-depth analysis of regenerative medicine and the challenges in translating it into clinical practice, with a focus on stem cell research, gene therapy and tissue engineering. It also includes insights into the late-stage R&D pipeline for regenerative medicine and the indications of particular interest in terms of development.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
GBI Research, the leading business intelligence provider, has released its latest research, “Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media”, which provides insights into the up-and-co ... more
GBI Research, leading business intelligence provider, has released its latest research report, entitled “Pharmaceutical Supply Chain in Europe - Adoption of Direct to Pharmacy (DTP) Model to Boost Efficiency and Optimize Pricing”. The report focuses on the current scenario of supply chain m ... more
GBI Research’s new report, “Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market”, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied various hurdle ... more
Fast-evolving biopharmaceuticals will challenge synthetic market dominance in the global market for active pharmaceutical ingredients (APIs), states a new report by business intelligence providers GBI Research.The new report "Active Pharmaceutical Ingredients (APIs) Global Market to 2017 - ... more
As the potential threat of biological terrorist attacks continues to command the attention of governments around the globe, anthrax and smallpox remain amongst the most researched diseases in the biodefense industry, states a new report by GBI Research.The company’s latest study shows that ... more
Avoidable care, incompetent hospital management and administrations scams accounted for an astonishing $800-$900 billion in unnecessary healthcare expenditure in the US last year, according to the latest findings of business intelligence experts GBI Research.
The new report, Pharmaceutical ... more